---
title: "TATT: Q2 2026 revenue up 22.8% YoY, net income up 134.5%, and backlog at $615M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294958174.md"
description: "Revenue grew 22.8% year-over-year in Q2 2026, with net income up 134.5% due to a one-time gain. Backlog reached $615M, supported by strong MRO and OEM demand, while all major segments posted growth except landing gear. Market outlook remains robust through 2032.Original document: TAT Technologies Ltd. [TATT] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T11:24:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294958174.md)
  - [en](https://longbridge.com/en/news/294958174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294958174.md)
generator: "portal-rs"
---

# TATT: Q2 2026 revenue up 22.8% YoY, net income up 134.5%, and backlog at $615M

Revenue grew 22.8% year-over-year in Q2 2026, with net income up 134.5% due to a one-time gain. Backlog reached $615M, supported by strong MRO and OEM demand, while all major segments posted growth except landing gear. Market outlook remains robust through 2032.

Original document: TAT Technologies Ltd. \[TATT\] Slides Release — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TATT.US](https://longbridge.com/en/quote/TATT.US.md)

## Related News & Research

- [Tat Technologies Highlights Q2 2026 Results and Growth Strategy in August Investor Update](https://longbridge.com/en/news/294969759.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [TLV: Strong H1 2026 profit growth and capital strength amid macroeconomic challenges](https://longbridge.com/en/news/296790736.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**